Lenka FialovÃ;

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1503307/publications.pdf Version: 2024-02-01



Ι ενικά Είλι ονά:

#	Article	IF	CITATIONS
1	Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology. JAMA Neurology, 2019, 76, 1035.	4.5	455
2	Oxidative stress, metabolism of ethanol and alcohol-related diseases. Journal of Biomedical Science, 2001, 8, 59-70.	2.6	273
3	Ethanol and Oxidative Stress. Alcoholism: Clinical and Experimental Research, 2001, 25, 237S-243S.	1.4	93
4	Oxidative stress and inflammation in pregnancy. Scandinavian Journal of Clinical and Laboratory Investigation, 2006, 66, 121-128.	0.6	60
5	Elevated intrathecal antibodies against the medium neurofilament subunit in multiple sclerosis. Journal of Neurology, 2007, 254, 20-25.	1.8	53
6	Relationship between ALS and the degree of cognitive impairment, markers of neurodegeneration and predictors for poor outcome. A prospective study. European Journal of Neurology, 2010, 17, 23-30.	1.7	49
7	Ethanol and oxidative stress. Alcoholism: Clinical and Experimental Research, 2001, 25, 237S-243S.	1.4	48
8	Glycoxidation and inflammation in chronic haemodialysis patients. Nephrology Dialysis Transplantation, 2003, 18, 2577-2581.	0.4	47
9	Serum and cerebrospinal fluid light neurofilaments and antibodies against them in clinically isolated syndrome and multiple sclerosis. Journal of Neuroimmunology, 2013, 262, 113-120.	1.1	47
10	Patients with Alzheimer disease have elevated intrathecal synthesis of antibodies against tau protein and heavy neurofilament. Journal of Neuroimmunology, 2012, 252, 100-105.	1.1	45
11	Cerebrospinal fluid and serum antibodies against neurofilaments in patients with amyotrophic lateral sclerosis. European Journal of Neurology, 2010, 17, 562-566.	1.7	42
12	Relationship of Pregnancy-Associated Plasma Protein-A to Renal Function and Dialysis Modalities. Kidney and Blood Pressure Research, 2004, 27, 88-95.	0.9	40
13	Antibodies against light neurofilaments in multiple sclerosis patients. Acta Neurologica Scandinavica, 2007, 116, 100-107.	1.0	40
14	Relationship between Increased Body Iron Stores, Oxidative Stress and Insulin Resistance in Healthy Men. Annals of Nutrition and Metabolism, 2009, 54, 268-274.	1.0	40
15	Increased levels of pregnancy-associated plasma protein-A in patients with hypercholesterolemia: the effect of atorvastatin treatment. American Heart Journal, 2003, 146, 1060-1063.	1.2	26
16	lron stores are associated with asymptomatic atherosclerosis in healthy men of primary prevention. European Journal of Clinical Investigation, 2011, 41, 846-853.	1.7	26
17	Increased Levels of Pregnancy-Associated Plasma Protein A Are Associated with Mortality in Hemodialysis Patients: Preliminary Results. Blood Purification, 2004, 22, 298-300.	0.9	25
18	Increased Intrathecal High-Avidity Anti-Tau Antibodies in Patients with Multiple Sclerosis. PLoS ONE, 2011, 6, e27476.	1.1	23

Lenka FialovÃi

#	Article	IF	CITATIONS
19	Relationship between advanced glycoxidation end products, inflammatory markers/acute-phase reactants, and some autoantibodies in chronic hemodialysis patients. Kidney International, 2003, 63, S62-S64.	2.6	21
20	Serum and cerebrospinal fluid heavy neurofilaments and antibodies against them in early multiple sclerosis. Journal of Neuroimmunology, 2013, 259, 81-87.	1.1	21
21	Comparison of different enzymeâ€linked immunosorbent assay methods for avidity determination of antiphospholipid antibodies. Journal of Clinical Laboratory Analysis, 2017, 31, .	0.9	21
22	Lower Serum Antibodies Against Tau Protein and Heavy Neurofilament in Alzheimer's Disease. Journal of Alzheimer's Disease, 2018, 64, 751-760.	1.2	20
23	Cerebrospinal fluid antibodies to tubulin are elevated in the patients with multiple sclerosis. European Journal of Neurology, 2008, 15, 1173-1179.	1.7	18
24	Oxidative stress, metabolism of ethanol and alcohol-related diseases. , 2001, 8, 59.		15
25	The weak association between neurofilament levels at multiple sclerosis onset and cognitive performance after 9 years. Multiple Sclerosis and Related Disorders, 2020, 46, 102534.	0.9	14
26	Avidity of anti-neurocytoskeletal antibodies in cerebrospinal fluid and serum. Folia Microbiologica, 2012, 57, 415-419.	1.1	11
27	Neurofilaments and tau proteins in cerebrospinal fluid and serum in dementias and neuroinflammation. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2017, 161, 286-295.	0.2	9
28	PAPP-A, a novel marker of unstable plaque, is not influenced by hypolipidemic treatment in contrast to CRP. Atherosclerosis, 2003, 166, 195-196.	0.4	8
29	Neuroprotective associations of apolipoproteins A-I and A-II with neurofilament levels in early multiple sclerosis. Journal of Clinical Lipidology, 2020, 14, 675-684.e2.	0.6	8
30	Antiphospholipid Antibodies in Patients with Lupus Nephritis. Renal Failure, 2003, 25, 747-758.	0.8	6
31	Avidity of antineurocytoskeletal antibodies in Alzheimer's disease patients. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2017, 161, 179-186.	0.2	4
32	Avidity of anticardiolipin antibodies-A factor that could be important for their detection by ELISA methods. Journal of Applied Biomedicine, 2014, 12, 277-284.	0.6	2
33	Avidity of anti-phospholipid antibodies in relation to their levels. Central-European Journal of Immunology, 2020, 45, 136-143.	0.4	1
34	Tu-P10:421 Antibodies to chlamydia pneumoniae in acute and chronic phase of myocardial infarction treated with PTCA. Atherosclerosis Supplements, 2006, 7, 277.	1.2	0
35	Levels and avidities of antiphosphatidylethanolamine antibodies in patients with thrombotic events and immunologically-mediated diseases. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2023, 167, 254-262.	0.2	0